Axa S.A. Invests $2.17 Million in Immunome, Inc. (NASDAQ:IMNM)

Axa S.A. acquired a new position in Immunome, Inc. (NASDAQ:IMNM) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 179,688 shares of the company’s stock, valued at approximately $2,174,000. Axa S.A. owned approximately 0.30% of Immunome at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Arizona State Retirement System grew its holdings in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the period. Clear Creek Financial Management LLC grew its stake in shares of Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after acquiring an additional 4,035 shares during the period. EntryPoint Capital LLC increased its holdings in Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after acquiring an additional 5,466 shares in the last quarter. Quest Partners LLC bought a new stake in Immunome during the 2nd quarter worth approximately $81,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Immunome during the second quarter valued at approximately $97,000. 44.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on IMNM shares. Piper Sandler reduced their price objective on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome currently has an average rating of “Buy” and an average target price of $29.00.

Insider Activity

In related news, CFO Max Rosett sold 14,380 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at $760,090.76. The sale was disclosed in a filing with the SEC, which is available through this link. In other Immunome news, Director Jean Jacques Bienaime acquired 7,000 shares of the company’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the purchase, the director now directly owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Immunome Price Performance

IMNM stock opened at $14.62 on Tuesday. The company has a market capitalization of $876.75 million, a price-to-earnings ratio of -1.94 and a beta of 1.77. Immunome, Inc. has a 1-year low of $6.93 and a 1-year high of $30.96. The business has a 50 day simple moving average of $14.59 and a two-hundred day simple moving average of $15.60.

Immunome (NASDAQ:IMNM) last posted its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The company had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. Sell-side analysts anticipate that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.